A new study has found that AF patients’ adverse event rates after having a coronary artery stent are alike regardless of whether the patient is using a drug-eluting or bare-metal device. In fact, in an online report posted on March 29 in the American  states that “systematic use of drug-eluting stents (DES) does not seem to be justified in most patients with AF because it was not associated with any clear advantage compared to bare-metal stents (BMS).”

This study was conducted by Dr. Laurent Fauchier and colleagues at Universite Francois Rabelais in Tours, France. They stated that even though a consensus guideline is against DES being used for AF patients (unless it is used for clinical or anatomic reasons), current evidence is not particularly conclusive on the matter yet. For the study, the researchers monitored 833 patients who have AF and had a PCI done. The researchers then kept track of the patients for a period of about 688 days, looking to catch the risks of them having any major adverse cardiac events.

It seems as if AF patients and their treatments continue to get complicated. With research constantly showing what works and what doesn’t, it is no wonder that drugs like Multaq are hardly being recommended unless other drugs don’t work. Even though catheter ablations are working out for some AF patients, many of them are still relying on prescription medications to help treat their AF symptoms. One of those medications, Multaq, has been under fire lately after the drug was proven to cause liver failure and a worsening of the heart condition.

If you or a loved on has developed liver failure or a worsening of the heart condition after taking Multaq, contact attorney Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.